Australia markets closed

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.94-0.44 (-6.90%)
At close: 04:00PM EDT
5.94 0.00 (0.00%)
After hours: 04:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.38
Open6.16
Bid5.90 x 200
Ask5.96 x 100
Day's range5.93 - 6.37
52-week range2.70 - 7.04
Volume582,288
Avg. volume289,726
Market cap379.136M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Bioventus Reports First Quarter Financial Results

    Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. “We ar

  • GlobeNewswire

    Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

    DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-8

  • GlobeNewswire

    Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

    Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing more than 20 years of leadership experience in the global medical device industryProvides full-year 2024 financial guidance reflecting enhanced revenue growth and improved execution DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today ann